PLD1 and glioblastoma: IHC evaluation indicated that treatment of mice bearing intracranial GBM derived from PLD1‐depleted GSCs with TMZ markedly decreased the expression of TMZ resistance factors (other than HOXA10) in intracranial GBM tumors, compared with that when only TMZ treatment was performed (supplementary material, Figure S5).